Bio-techne share price today

(TECH)

Bio-techne share price is $75.69 & ₹6,415.56 as on 14 Dec 2024, 2.30 'hrs' IST

$75.69

▲

-0.99

(-1.29%)

Market is closed - opens 8 PM, 16 Dec 2024

View live Bio-techne share price in Dollar and Rupees. Guide to invest in Bio-techne from India. Also see the sentimental analysis on Indian investors investing in Bio-techne. Get details on the Indian mutual funds that are investing in Bio-techne. Get Analyst recommendations and forecasts along with all the Bio-techne's financials.

Bio-techne share price movements

$74.41
$76.54
$75.69
1.69%
Downside
Day's Volatility :2.78%
Upside
1.11%
$61.16
$85.57
$75.69
19.2%
Downside
52 Weeks Volatility :28.53%
Upside
11.55%

Bio-techne Returns

Period	Bio-techne Corp.	Sector (Health Care)	S&P500
3 Months	1.24%	-9.7%	7.6%
6 Months	1.18%	-3.3%	11.4%
1 Year	-0.39%	4.2%	28.2%
3 Years	-36.19%	4.2%	30.6%

Bio-techne Key Statistics

in dollars & INR

Previous Close	$76.68
Open	$76.58
Today's High	$76.54
Today's Low	$74.41
Market Capitalization	$12.2B
Today's Volume	$480.8K
52 Week High	$85.57
52 Week Low	$61.16
Revenue TTM	$1.2B
EBITDA	$308.5M
Earnings Per Share (EPS)	$0.95
PE Ratio	80.72
Dividend Yield	0.42%
Profit Margin	12.86%
Quarterly Earnings Growth YOY	-0.32%
Return On Equity TTM	7.29%

How to invest in Bio-techne from India?

It is very easy for Indian residents to invest directly in Bio-techne from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bio-techne stock in both rupees (INR) and dollars (USD). Search for Bio-techne or TECH on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bio-techne or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bio-techne shares which would translate to 0.011 fractional shares of Bio-techne as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Bio-techne

15%

Period: Sep 14, 2024 to Dec 13, 2024. Change in 30 Days versus previous period

Search volume for Bio-techne on INDmoney from India has grown in the last 30 days as on Dec 14, 2024. 15% more investors are searching Bio-techne in the last 30 days versus the previous period.

Indian Mutual Funds that Invest in Bio-techne

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	1354	-2.46	0.02%

Global Institutional Holdings in Bio-techne

Vanguard Group Inc
11.53%
BlackRock Inc
9.43%
T. Rowe Price Associates, Inc.
5.93%
State Street Corp
4.03%
Morgan Stanley - Brokerage Accounts
2.93%
BAMCO Inc
2.80%

Analyst Recommendation on Bio-techne

Buy

84%Buy

15%Hold

0%Sell

Based on 19 Wall street analysts offering stock ratings for Bio-techne(by analysts ranked 0 to 5 stars)

Based on 19 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Bio-techne

What analysts predicted

Upside of 12.63%

Current:

$75.69

Target:

$85.25

Insights on Bio-techne

Price Movement
In the last 7 days, TECH stock has moved up by 2.9%
Decreasing Revenue
Revenue is down for the last 2 quarters, 306.09M → 289.45M (in $), with an average decrease of 5.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 49.05M → 33.6M (in $), with an average decrease of 17.2% per quarter
TECH vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 31.5% return, outperforming this stock by 29.3%
TECH vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 65.8%
Price to Sales
ForTECH every $1 of sales, investors are willing to pay $10.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Bio-techne Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$714.0M	↑ 11.04%
Net Income	$96.1M	↓ 23.36%
Net Profit Margin	13.46%	↓ 6.03%

	FY20	Y/Y Change
Revenue	$738.7M	↑ 3.46%
Net Income	$229.3M	↑ 138.67%
Net Profit Margin	31.04%	↑ 17.58%

	FY21	Y/Y Change
Revenue	$931.0M	↑ 26.04%
Net Income	$140.4M	↓ 38.76%
Net Profit Margin	15.08%	↓ 15.96%

	FY22	Y/Y Change
Revenue	$1.1B	↑ 18.75%
Net Income	$272.1M	↑ 93.75%
Net Profit Margin	24.61%	↑ 9.53%

	FY23	Y/Y Change
Revenue	$1.1B	↑ 2.81%
Net Income	$285.3M	↑ 4.86%
Net Profit Margin	25.1%	↑ 0.49%

	FY24	Y/Y Change
Revenue	$1.2B	↑ 1.97%
Net Income	$168.1M	↓ 41.07%
Net Profit Margin	14.5%	↓ 10.6%

	Q2 FY23	Q/Q Change
Revenue	$301.3M	↑ 2.44%
Net Income	$75.5M	↑ 7.5%
Net Profit Margin	25.05%	↑ 1.18%

	Q3 FY23	Q/Q Change
Revenue	$276.9M	↓ 8.09%
Net Income	$51.0M	↓ 32.45%
Net Profit Margin	18.41%	↓ 6.64%

	Q4 FY23	Q/Q Change
Revenue	$272.6M	↓ 1.57%
Net Income	$27.5M	↓ 46.14%
Net Profit Margin	10.08%	↓ 8.33%

	Q1 FY24	Q/Q Change
Revenue	$303.4M	↑ 11.31%
Net Income	$49.1M	↑ 78.62%
Net Profit Margin	16.17%	↑ 6.09%

	Q2 FY24	Q/Q Change
Revenue	$306.1M	↑ 0.88%
Net Income	$40.6M	↓ 17.27%
Net Profit Margin	13.26%	↓ 2.91%

	Q3 FY24	Q/Q Change
Revenue	$289.5M	↓ 5.44%
Net Income	$33.6M	↓ 17.22%
Net Profit Margin	11.61%	↓ 1.65%

	FY19	Y/Y Change
Profit	$473.5M	↑ 9.57%

	FY20	Y/Y Change
Profit	$483.2M	↑ 2.05%

	FY21	Y/Y Change
Profit	$632.9M	↑ 30.97%

	FY22	Y/Y Change
Profit	$756.5M	↑ 19.54%

	FY23	Y/Y Change
Profit	$769.8M	↑ 1.76%

	FY24	Y/Y Change
Profit	$769.7M	↓ 0.01%

	Q2 FY23	Q/Q Change
Profit	$204.7M	↑ 1.25%

	Q3 FY23	Q/Q Change
Profit	$185.2M	↓ 9.53%

	Q4 FY23	Q/Q Change
Profit	$176.6M	↓ 4.65%

	Q1 FY24	Q/Q Change
Profit	$205.2M	↑ 16.23%

	Q2 FY24	Q/Q Change
Profit	$204.9M	↓ 0.18%

	Q3 FY24	Q/Q Change
Profit	$183.0M	↓ 10.67%

	FY19	Y/Y Change
Operating Cash Flow	$181.6M	↑ 6.6%
Investing Cash Flow	$-336.8M	↑ 770.01%
Financing Cash Flow	$134.4M	↓ 235.48%

	FY20	Y/Y Change
Operating Cash Flow	$205.2M	↑ 12.99%
Investing Cash Flow	$27.1M	↓ 108.04%
Financing Cash Flow	$-183.8M	↓ 236.77%

	FY21	Y/Y Change
Operating Cash Flow	$352.2M	↑ 71.61%
Investing Cash Flow	$-243.5M	↓ 998.75%
Financing Cash Flow	$-62.6M	↓ 65.97%

	FY22	Y/Y Change
Operating Cash Flow	$325.3M	↓ 7.64%
Investing Cash Flow	$-96.9M	↓ 60.23%
Financing Cash Flow	$-242.9M	↑ 288.25%

	FY23	Y/Y Change
Operating Cash Flow	$254.4M	↓ 21.79%
Investing Cash Flow	$-265.6M	↑ 174.29%
Financing Cash Flow	$22.6M	↓ 109.31%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$83.4M	↑ 65.02%
Investing Cash Flow	$-4.8M	↓ 98.03%
Financing Cash Flow	$-24.2M	↓ 116.06%

Bio-techne Technicals Summary

Sell

Neutral

Buy

Bio-techne is currently in a neutral trading position according to technical analysis indicators.

Bio-techne Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bio-techne Corp.	4.34%	1.18%	-0.39%	-36.19%	38.33%
Regeneron Pharmaceuticals, Inc.	-6.54%	-30.04%	-14.88%	11.15%	94.49%
Biontech Se	16.24%	36.11%	17.79%	-58.06%	243.94%
Alnylam Pharmaceuticals, Inc.	-4.84%	56.03%	32.5%	28.46%	104.33%
Vertex Pharmaceuticals Incorporated	-4.18%	-2.1%	12.92%	119.64%	111.27%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bio-techne Corp.	80.72	80.72	2.82	1.78	0.07	0.06	0.0	13.46
Regeneron Pharmaceuticals, Inc.	19.12	19.12	1.15	45.03	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bio-techne Corp.	Buy	$12.2B	38.33%	80.72	12.86%
Regeneron Pharmaceuticals, Inc.	Buy	$84.9B	94.49%	19.12	33.61%
Biontech Se	Buy	$28.9B	243.94%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.8B	104.33%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	111.27%	32.84	-4.51%

Bio-techne Dividend announcements

Bio-techne Dividends December, 2024
In the quarter ending December,2024. Bio-techne has declared dividend of $0.08
Read More

About Bio-techne

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Organization	Bio-techne
Employees	3100
CEO	Mr. Kim Kelderman
Industry	Health Technology

Management People of Bio-techne

Name	Title
Mr. Kim Kelderman	CEO, President & Director
Mr. James T. Hippel CPA	Executive VP of Finance & CFO
Mr. Shane Bohnen	Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer
Mr. William A. Geist	President of Protein Sciences Segment
Dr. Matthew F. McManus M.D., MBA, Ph.D.	President of Diagnostics & Genomics
Dr. Gary J. Latham Ph.D.	VP & CTO
Mr. David Clair C.F.A.	Senior Director of Investor Relations & Corporate Development
Mr. Gerry Andros	Vice President of Sales and Marketing
Mr. Martin Wirtz	Senior Vice President of Strategy & Corporate Development
Ms. Cheryl Bethune	Senior VP & Chief Human Resources Officer

Important FAQs about investing in Bio-techne from India :

What is Bio-techne share price today?

Bio-techne share price today stands at $75.69, Open: $76.58 ; Previous Close: $76.68 ; High: $76.54 ; Low: $74.41 ; 52 Week High: $85.57 ; 52 Week Low: $61.16. The stock opens at $76.58, after a previous close of $76.68. The stock reached a daily high of $76.54 and a low of $74.41, with a 52-week high of $85.57 and a 52-week low of $61.16.

Can Indians buy Bio-techne shares?

Yes, Indians can invest in the Bio-techne (TECH) from India.

With INDmoney, you can buy Bio-techne at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bio-techne at zero transaction cost.

How can I buy Bio-techne shares from India?

It is very easy to buy Bio-techne from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bio-techne be purchased?

Yes, you can buy fractional shares of Bio-techne with INDmoney app.

What are the documents required to start investing in Bio-techne stocks?

To start investing in Bio-techne, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.